Appendix l-B— A Timetable for the Commercial Production of Compounds • 285 
Table l-B-22.— Viral Antigens: Technical Information 
Compound 
Typical synthetic 
process 
Typical precursor 
Is precursor 
renewable/non- 
reneywable 
limited 
Alternate 
precursor by 
fermentation 
Time to implement 
commercial fermentation by 
genetically engineered 
strain 
Avian leukemia. . . 
virus 
Avian 
myeloblastosis. 
virus 
(Information not available) 
(Information not available) 
glucose 
and NH/® 
glucose 
and NHx"" 
5yrs. 
5yrs. 
Epstein-Barr virus 
tissue culture 
lymphoblasts 
renewable 
glucose 
and NH/ 
5 yrs. 
Hepatitis 
viruses 
(Information not available) 
glucose 
and NHx"^ 
5 yrs. 
Herpes 
viruses 
(Information not available) 
glucose 
and NH4+ 
5 yrs. 
Hoof and mouth . . 
disease virus 
(Information not available) 
glucose 
and NHx^ 
5 yrs. 
Influenza 
viruses 
(Information not available) 
glucose 
and NHx^ 
10 yrs. 
Reoviruses 
(Information not available) 
glucose 
and NH/ 
15 yrs. 
Rous sarcoma . . . 
virus 
(Information not available) 
glucose 
and NH4+ 
5 yrs. 
Rubella 
virus 
tissue culture 
duck embryonic 
cells 
renewable 
glucose 
and NH4+ 
5 yrs. 
Varicella 
virus 
(Information not available) 
glucose 
NH4-" 
5 yrs. 
^Ammonium ion. 
SOURCE: Compiled by Cenex Corp, from data in references 4 and 25. 
Table l-B-23.— Short Peptides, Nucleotides, and 
Miscellaneous Proteins: Market Information 
Current market data 
Market 
volume Bulk cost Market value 
Product category 1,0001b $/lb ($ millions) 
Short peptides^ 
Aspartame 40 110.00 4.4 
Glycine-histidine- 
lysine (Information not available) 
Nucleotides^’ 
5’-IMPc 4,000 12.00 48.0 
5'-GMPd 2,000 12.00 24.0 
Miscellaneous proteins^ 
Interferon N/A N/A 50.0 
Human serum 
albumin 250 1,000.00 250.0 
Monoclonal 
antibodies (Information not available) 
^Data from references 4 and 26. 
j ^Data from references 4 and 27. 
•' '-5'-inosinic acid. 
'^5’-guanylic acid. 
®Data from reference 4. 
SOURCE: Compiled by Cenex Corp. 
'] 
|i 
